Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
  • C07K16/081—DNA viruses
  • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
  • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
  • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N5/10—Cells modified by introduction of foreign genetic material
  • C12N5/12—Fused cells, e.g. hybridomas
  • C12N5/16—Animal cells
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
  • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
  • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
  • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
  • C12N2710/00011—Details
  • C12N2710/20011—Papillomaviridae
  • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
  • C12N2710/00011—Details
  • C12N2710/20011—Papillomaviridae
  • C12N2710/20023—Virus like particles [VLP]
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
  • G01N2333/01—DNA viruses
  • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2800/00—Detection or diagnosis of diseases
  • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2800/00—Detection or diagnosis of diseases
  • G01N2800/54—Determining the risk of relapse
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
  • G01N33/56983—Viruses

Definitions

• the present invention relates to a method for therapy control of HPV16 positive carcinoma, an antibody for use in the corresponding diagnostic method as well as a test for performing the method.
• the present invention relates to a serologic method for monitoring the development of the amount of antibodies in samples, which were taken from a patient before and after the treatment of a HPV16 positive carcinoma over a predetermined period of time.
• the invention provides an immunologic test in the form of a kit, with which the method according to the invention can be performed.
• HPV human papilloma viruses
• HPV infections are widely spread and different HPV types are attributed to different clinical pictures.
• HPV of type 1 and HPV of type 2 cause warts on the hands and feet, while HPV of type 6 and HPV of type 1 1 genital warts. In many cases, such an infection has no clinical symptoms, but it can also result in a tumor-like growth of the affected epithelial cells.
• HPVs can also cause malignant changes and therefore be responsible for the development of cancer, for example in the genital region but also in the mouth or throat.
• Therapy method of choice for these malignant tumors is surgery, radiotherapy, chemotherapy, immunotherapy or a combination of these methods.
• therapy control after treatment of HPV positive carcinoma it is desirable to detect tumor cells remaining in the body but also a relapse or metastases early, so that treatment can be resumed, for example by chemotherapy or immunotherapy, before visible secondary tumors are formed.
• tumor antigens i.e. particular antigen structures, that are part of a tumor cell and specific for it, and which are recognized by the immune system and can cause an immune response.
• tumor antigens HPV E6 and HPV E7 are only suitable to a limited extent, however, because these protein antigens occur in all HPV types, are largely homologous and therefore do not allow a type specific assessment, not even when, for example, HPV16 specific E6 or E7 proteins are used for serologic detection.
• HPV are dsDNA viruses.
• the non-encapsulated virions consist of icosahedral capsids.
• L1 late protein 1 determines - amongst other things - the capsid formation of the HPV and is primarily responsible for the immunogenicity of HPV types.
• HPV16 capsid antibodies The presence of a larger amount of HPV16 capsid antibodies in the serum is associated with a higher risk for the occurrence of cervix carcinoma. It was also found in the tests that the HPV16 capsid antibodies did not recede noticeably over a period of 7 to 13 years.
• L1 or also the main capsid protein of HPV can be in mono- meric or multimeric form. Fife single L1 proteins associate to build so-called capsomers (or pentamers). 72 capsomers, as sub-units of the capsids, associate to form the capsid of the viruses, in which the genetic material is packed during naturally occurring infection. Differences in the nucleic acid sequence of 10% within the L1 gene are defined as a requirement in order to describe a new HPV type. This means, that even different HPV types may be identical in almost 90% of the L1 gene and protein. Besides the main capsid protein (L1 ), there is also the minor capsid protein L2. The L2 protein is also a highly conserved, i.e. in large parts identical protein. The L2 protein is therefore also not specific for particular HPV types.
• type-specific and non-type-specific L1 antibodies can not be distinguished when using monomeric L1 proteins in a " traditional ' arrangement of an ELISA test with peroxidase or fluorescent labeled anti-lgG specific conjugates.
• Merely the presence of anti-L1 antibodies of the more than 100 different HPV is detected, even if the L1 protein is derived from HPV type 16. Because of the very high homology of the protein within the group of HPV, the seeming type specificity of the used L1 antigen is very misleading.
• HPV serology is not suitable for therapy control of HPV16 positive carcinoma because it is accepted in the state of the art, that the amount of antibodies remains stable over years and does not necessarily decrease after therapy, so that this parameter is not suitable for a monitoring the condition.
• the different HPV types can not be distinguished using conventional antibody tests.
• HPV16 L1 capsid specific antibodies which bind to at least one conformational epitope of the HPV16 L1 capsid, which is not present in monomeric and/or denatured HPV16 L1 proteins, a decrease and a rebound of the amount of antibodies is observed.
• HPV16 L1 capsid specific antibodies which bind to at least one conformational epitope of the HPV16 L1 capsid, which is not present in monomeric and/or denatured HPV16 L1 proteins
• the problem to be solved by the present invention was to provide a serologic test, which allows a highly sensitive and type specific therapy control of HPV16 positive carcinoma and facilitates detection of a reoccurrence of the disease, such as a relapse or a metas- tasis, at an early stage.
• a sample may be taken from the patient before the treatment or at the time the anticancer therapy is initiated, to obtain a reference value of the amount of antibodies in the sample, to which later samples can be compared. Antibody levels as high as up to 50 000 ng/ml may be observed at this time in a patient.
• the binding of antibodies in the sample bound to the antigen is detected by contacting the sample with labeled antibodies that specifically bind to the conformational epitope of the HPV16 L1 capsid or capsomer, preferably with labeled antibodies obtained from the hybridoma cell line with the deposit number DSM ACC3306.
• the binding of said antibodies is compared with a reference level of binding, preferably wherein the binding of said antibodies is compared with the binding of said antibodies in one or more samples taken from said patient at predetermined time intervals, wherein a decrease in said binding over a predetermined time indicates successful anti-cancer therapy and wherein an increase in said binding over time indicates a recurrence of the HPV16- positive carcinoma in said patient.
• the labeled antibodies may be present in mobile form on a test strip and wherein complexes of antigen and labeled antibody are detected by binding to another antibody, preferably wherein the other antibodies are also ones that are obtained from the hybridoma cell line with the deposit number DSM ACC3306.
• a patient identified as having a recur- rence of the HPV16 positive carcinoma may be administered an anti-cancer therapy.
• the method for therapy control after treatment of HPV16 positive carcinoma comprises or consists of the following steps: i) Mixing a sample of a patient with a plurality of antigens, wherein the antigens present HPV16 L1 capsid or capsomer structures, which have conformational epitopes not present in monomeric and/or denatured HPV16 L1 , under conditions at which antibodies present in the sample can bind to the HPV16 L1 antigens, ii) Contacting the mixture of step i) with labeled antibodies, which specifically bind to the conformational epitopes of the HPV16 L1 capsid or capsomer structure presenting antigens, particularly with labeled antibodies, which are obtained from the hybridoma cell line with the deposit number DSM ACC3306, iii) Quantifying the labeled antibodies and/or the antibodies of the sample, which have bound to the HPV16-L1 capsid or capsomer structure presenting antigens, respectively,
• the method according to the invention allows to quantify the amount of antibodies in the sample of the patient over a period of time and thus to track the development of the condition after therapy. For example, steps i) to iii) can be repeated every 1 to 4 weeks over a period of one to ten years. In case of a successful therapy, the amount of antibodies found in the sample of the patient may decrease by over 50 % within a couple of weeks compared to the amount of antibodies found before or at the beginning of the treatment.
• antigens or virus like particles can be used, which present the HPV16 L1 capsid or capsomer structures, having conformational epitopes.
• the conformational epitopes specifically bind antibodies, which are obtained from the hybridoma cell line with the deposit number DSM ACC3306.
• a body fluid is suitable, e.g. whole blood or derivatives of whole blood such as, e.g. serum or plasma, as well as capillary blood or whole blood from the finger pad of the patient.
• whole blood or derivatives of whole blood such as, e.g. serum or plasma
• capillary blood or whole blood from the finger pad of the patient e.g. whole blood or derivatives of whole blood such as, e.g. serum or plasma
• capillary blood or whole blood from the finger pad of the patient e.g. serum or plasma
• step i) the sample of the patient can be incubated over a period of 1 to 15 minutes, preferably, 3 to 10 minutes. Thus, specific interactions are ensured.
• the therapy is in particular a primary therapy by surgery, radiotherapy, chemotherapy or immunotherapy or a combination of these methods.
• an HPV16 L1 capsid or capsomer structure is an aggregate or a multimer of the HPV16 L1 protein, which, by interaction of several L1 proteins, forms conformational epitopes on its surface, which are not present in L1 monomers or denatured proteins.
• virus like particles VLPs
• Some VLPs may carry several of the conformational epitopes, i.e. specific binding sites.
• VLP virus like particle
• a virus like particle in the context of the present invention, is a virus particle, which consists of viral capsids, but does not contain nucleic acids.
• the VLPs are therefore suitable to present the above mentioned conformational epitopes without being capable of replication.
• the labeled antibodies are antibodies directed against the HPV16 L1 , which specifically binds to the conformational epitopes of the HPV L1 capsid or capsomer structures and thus not to monomeric and/or dentatured HPV16 L1 proteins.
• a preferred antibody according to the invention can be obtained from the hybridoma cell line, which was deposited under the Budapest Treaty at the Deutsche Sammlung fur Mikroorganismen und Zellkulturen (DSMZ). InhoffenstraBe 7B, 38124 Braunschweig, Germany, on 14 Septem- ber 2016 by Abviris Germany, Ammersbeck, under the deposit number DSM ACC3306.
• DSMZ Deutsche Sammlung fur Mikroorganismen und Zellkulturen
• the skilled person is aware of suitable methods of the state of the art, which allow a quantification of the amount of bound and unbound antibodies.
• the method is absolutely specific for HPV type 16 and there is no cross-reaction with other antibodies.
• the reason for this is in particular, that the capsomer structures are present as L1 aggregates, whereby the conformational epitopes are presented on the surface.
• L1 protein forms aggregates (synonyms are multimers, pentamers or also capsomers), structures (conformational epitopes - binding sites for antibodies) are formed on the surface (the areas of the capsids that are oriented towards the outside) of these aggregates by interaction of several L1 proteins, which are specific for particular HPV types (i.e. type specific).
• the highly homologous areas of the L1 protein are oriented such that they are not on the surface but in the inside. These areas are necessary for the integration of the viral genetic material. That means, that for the viruses or the non-infectious virus like particles (VLPs) used in testing, the above described areas, which strongly match within the family of the papilloma viruses, are hidden inside the particles. These areas are thus no longer accessible in VLPs for the group specific antibodies in the human samples, whereby it is ensured that exclusively type specific antibodies are detectable.
• monomeric protein can not be removed by 100% during VLP purification. Purified VLPs therefore always contain also capsomers. This means, that if these purified L1 proteins are directly immobilized on a carrier medium (e.g. on classic ELISA plates), both, type specific VLPs but also monomeric L1 protein and capsomers with non-type specific areas are available for testing.
• VLPs which consist of the L1 and the L2 protein.
• the antigens are not immobilized but are provided in a liquid phase, to which the patient sample is added.
• VLPs antigens
• the antibodies of the patient sample and the antigen come into close proximity.
• the kinetics of the binding reaction become significantly faster, which is extremely useful for a quick test.
• the analytic sensitivity is increased because all antibodies in the patient sample are ' quickly ' available for the testing.
• a carrier material e.g. a microtiter plate
• the antibodies in close proximity to the surface are available as reactants.
• the antibodies within the lumen of the reaction vessel will practically ' never ' reach the surface of the reaction vessel because they have to cross the distance of 1-2 mm to the surface exclusively by Brownian motion, which takes ' a lot ' of time.
• step iii) the mixture runs across a test strip, on which the labeled antibodies are present in mobile form and wherein in step iii) complexes of antigen and labeled antibody are detected by binding to another antibody, wherein preferably the other antibodies are also ones that are obtained from the hybridoma cell line with the deposit number DSM ACC3306.
• This embodiment allows to provide a quick test, in which in a reaction zone, a quickly readable test result line becomes visible.
• the mixture of step i) is applied at an application area on the test strip and then runs, for example by using capillary forces, across a membrane, during which it comes into contact with the labeled antibodies on a stretch up to the reaction zone.
• the labeled antibodies are concentrated such that not all antigens or binding sited are filled up.
• further antibodies are immobilized, which are also specific for the antigens or binding sites according to the invention and bind the labeled antibody-antigen complexes, insofar as free binding sites are still available.
• the labeled antibody-antigen complexes are retained in the reaction zone, whereby a test line becomes visible.
• the antigens or binding sites, respectively are already occupied by antibodies from the pa- tient sample, due to the competitive approach, less antibody-antigen complexes are formed with the labeled antibodies and the test line is less intense or not visible at all, that is, in case all binding sites were already occupied by the antibodies from the patient sample at the time of application.
• the correct adjustment of the amount of antigens or binding sites, respectively, in step i) and labeled antibodies in step ii) is important in this context, so that a change in the amount of antibodies in the patient sample with respect to a previous measurement can be detected.
• the present invention also relates to a method of treating a patient that has previously been administered at least one anti-cancer therapy targeting an HPV16-positive carcinoma comprising (A) requesting a test providing results of an analysis to determine whether the patient has an increase in antibodies that bind to a conformational epitope of HPV16 L1 capsid or capsomer over a predetermined time period and (B) administering an additional anti-cancer therapy targeting HPV16-positive carcinoma if an increase in antibodies is detected in the patient.
• the present invention also relates to an antibody, which specifically binds to conformational epitopes of HPV16-L1 capsid or capsomer structure presenting antigens, preferably an antibody, which is obtained from the hybridoma cell line with the deposit number DSM ACC3306.
• the present invention also relates to an antibody as described above for use in a diagnostic method, in particular in a method for determining the reoccurrence of a HPV16- positive carcinoma after treatment.
• the present invention also relates to an antigen, which presents HPV16 L1 capsid or capsomer structures or a virus like particle. which presents the HPV16 L1 capsid or capsomer structures.
• the invention further relates to an antigen or a virus like particle as described above for use in a diagnostic method, in particular in a method for determining the reoccurrence of a HPV16- positive carcinoma after treatment.
• the present invention further related to a kit for determining an amount of antibodies in a sample of a patient comprising or consisting of:
• composition comprising antigens presenting conformational epitopes of HPV16 L1 capsid or capsomer structures
• composition II a composition comprising labeled antibodies, which specifically bind to conformational epitopes of HPV16 L1 capsid or capsomer structure presenting antigens, wherein preferably the labelled antibodies are obtained from the hybridoma cell line with the deposit number DSM ACC3306.
• the composition i) is preferably a composition, which comprises virus like particles, which present conformational epitopes of HPV16 L1 capsid or capsomer structures.
• a kit according to the invention can also comprise a test strip, which optionally is provided in a testing cassette, which has openings for applying the mixture of step i) as well as for observing a test line and preferably a control line.
• the test strip comprises on one end an application zone for the mixture of step i), a pad, on which the labeled antibodies are provided and which connects to the application zone, as well as a reaction zone, which connects on the other side of the pad when viewed from the application zone and preferably a control zone, further beyond the reaction zone.
• the further antibody is provided, which specifically binds the epitope according to the invention and by binding of the labeled antibody-antigen complexes makes the test line visible.
• Another independent antibody reaction in the control zone shows that the test proceeded correctly. The appearance of a line in the control zone confirms that the sample volume was sufficient and the test ran as intended.
• Figure 1 shows the development of the amount of antibodies in the serum of a patient with a positive therapy course over 27 weeks after primary therapy of a HPV16 positive carcinoma.
• the weeks starting from 0 at the point in time of the primary therapy are shown
• the concentration of the antibody according to the invention is shown in ng/ml.
• Figure 2 shows the development of the amount of antibodies in the serum of a patient, in which after about 35 weeks after the primary therapy of a HPV16 positive carcinoma, a relapse occurred. Up to week 27, a continuous decrease of the amount of antibodies was observed. Beginning in week 31 , the amount of antibodies increased again. The increase continued until week 35, at which time the clinical correlation was found. On the X axis, the weeks starting from 0 at the point in time of the primary therapy are shown, on the Y axis, the concentration of the antibody according to the invention is shown in ng/ml.
• Example 1 Scjreemnq for the anjibgdjes an ⁇ antiqens accordingjgjhejnventioin
• VLPs papiilom virus like particles
• VLPs Virus like particles
• Volpers et al.. Volpers, C, P. Schirmacher, R. E. Streeck, and M. Sapp. 1994. Assembly of the major and the minor Kapsid protein of human papilloma virus type 33 into virus-like particles and tubular structures in insect cells. Virology 200:504-512). Production, screening and cloning of the monoclonal antibodies.
• BALB/c mice were subcutaneously immunized with 20pg of intact HPV16 VLPs dissolved in phosphate buffered salt solution (PBS), after these had been mixed with complete Freund ' s adjuvant. The immunization was repeated after one month and after three months.
• PBS phosphate buffered salt solution
• the spleen cells were fused with the mouse myeloma cell line X63Ag8.653 using polyethylene glycol 2500 (Boehringer Mannheim) and cultured in Iscoves modified Eagle Medium (IMDM) in the presence of 10% fetal calf serum in 96- well plates. Fused cells were selected with azaserine and hypoxanthine. After 6 to 8 days, the supernatant of the cells was tested for secretion of HPV16 L1 specific antibodies using ELISA. Denatured L1 protein, as well as VLPs of HPV-6, HPV-1 1 , HPV-18, HPV-31 , HPV-33 and HPV-39 served as controls to exclude unspecific reactivities.
• IMDM Iscoves modified Eagle Medium

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Immunology (AREA)
• Biomedical Technology (AREA)
• Molecular Biology (AREA)
• Genetics & Genomics (AREA)
• Organic Chemistry (AREA)
• Biotechnology (AREA)
• Biochemistry (AREA)
• General Health & Medical Sciences (AREA)
• Urology & Nephrology (AREA)
• Hematology (AREA)
• Microbiology (AREA)
• Medicinal Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Cell Biology (AREA)
• Physics & Mathematics (AREA)
• Pathology (AREA)
• Analytical Chemistry (AREA)
• General Physics & Mathematics (AREA)
• Food Science & Technology (AREA)
• General Engineering & Computer Science (AREA)
• Virology (AREA)
• Biophysics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Plant Pathology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Peptides Or Proteins (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Priority Applications (20)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=61027644

Family Applications (1)

Country Status (22)

Cited By (1)

Family Cites Families (7)

• 2016
  • 2016-12-13 DE DE102016124171.7A patent/DE102016124171A1/de not_active Withdrawn
• 2017
  • 2017-12-13 PT PT178356028T patent/PT3384292T/pt unknown
  • 2017-12-13 DK DK17835602.8T patent/DK3384292T3/da active
  • 2017-12-13 US US16/090,159 patent/US10852303B2/en active Active
  • 2017-12-13 SM SM20210421T patent/SMT202100421T1/it unknown
  • 2017-12-13 BR BR112019011681-8A patent/BR112019011681A2/pt not_active IP Right Cessation
  • 2017-12-13 PL PL17835602T patent/PL3384292T3/pl unknown
  • 2017-12-13 SI SI201730846T patent/SI3384292T1/sl unknown
  • 2017-12-13 WO PCT/EP2017/082506 patent/WO2018108957A1/en not_active Ceased
  • 2017-12-13 EP EP17835602.8A patent/EP3384292B1/en active Active
  • 2017-12-13 KR KR1020197020463A patent/KR102433541B1/ko active Active
  • 2017-12-13 CA CA3045729A patent/CA3045729A1/en active Pending
  • 2017-12-13 HR HRP20211080TT patent/HRP20211080T1/hr unknown
  • 2017-12-13 ES ES17835602T patent/ES2880489T3/es active Active
  • 2017-12-13 JP JP2019532928A patent/JP7329244B2/ja active Active
  • 2017-12-13 CN CN201780077269.1A patent/CN110073219B/zh not_active Expired - Fee Related
  • 2017-12-13 RU RU2019121882A patent/RU2757629C2/ru active
  • 2017-12-13 HU HUE17835602A patent/HUE054969T2/hu unknown
  • 2017-12-13 RS RS20210859A patent/RS62135B1/sr unknown
  • 2017-12-13 LT LTEP17835602.8T patent/LT3384292T/lt unknown
• 2018
  • 2018-07-06 ZA ZA2018/04516A patent/ZA201804516B/en unknown
• 2020
  • 2020-09-09 US US17/015,955 patent/US11506667B2/en active Active
• 2021
  • 2021-07-06 CY CY20211100609T patent/CY1124297T1/el unknown
• 2022
  • 2022-12-15 JP JP2022200001A patent/JP2023029377A/ja active Pending

Non-Patent Citations (7)

Also Published As

Similar Documents

Legal Events